SureNano Science Initiates FDA Stage GLP Toxicology and Pharmacology Studies for GLP GEP-44 and Enters Discussions to Acquire Ibogaine Formulation IP Portfolio
Global Partners LP(US:GLP) TMX Newsfile·2026-04-24 20:00GLP-compliant program covering rodents, non-rodents, and primates will define safety, MTD and safe dose ranges, targeting weight loss and TIIDMNovel Ibogaine formulation development for mental health treatment including addiction Studies support upcoming regulatory submission and initiation of Phase I trial in AustraliaVancouver, British Columbia--(Newsfile Corp. - April 24, 2026) - SureNano Science Ltd. (CSE: SURE) (OTCQB: SURNF) ("SureNano" or the "Company"), parent company of GlucaPharm Inc. ("GlucaPhar ...